During the past decade, National Institute of Cancer conducted 20 clinical trials. In the 10-year time frame, 20 clinical trials started and 8 clinical trials were completed, i.e. on average, 40% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 5 clinical trials were completed. i.e. 62.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "National Institute of Cancer" #1 sponsor was "Janssen Research & Development, LLC" with 4 trials, followed by "Bayer" with 3 trials sponsored, "Boehringer Ingelheim" with 2 trials sponsored, "Merck Sharp & Dohme LLC" with 2 trials sponsored and "Pfizer" with 2 trials sponsored. Other sponsors include 6 different institutions and companies that sponsored additional 16 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "National Institute of Cancer" #1 collaborator was "Astellas Pharma Global Development, Inc." with 1 trials as a collaborator, "European Organisation for Research and Treatment of Cancer - EORTC" with 1 trials as a collaborator, "Merck Sharp & Dohme LLC" with 1 trials as a collaborator, "Seagen Inc." with 1 trials as a collaborator and "University of Jena" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "National Institute of Cancer" are "Carcinoma, Non-Small-Cell Lung" (3 trials), "Melanoma" (2 trials), "Solid Tumors Harboring NTRK Fusion" (2 trials), "Urinary Bladder Cancer, Muscle-invasive" (2 trials) and "B-cell Non-Hodgkin's Lymphoma" (1 trials). Many other conditions were trialed in "National Institute of Cancer" in a lesser frequency.

Most popular intervention types in "National Institute of Cancer" are "Drug" (20 trials), "Procedure" (2 trials), "Biological" (1 trials), "Device" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Pembrolizumab" (4 trials), "Placebo" (4 trials), "Amivantamab" (2 trials), "Avastin" (2 trials) and "BI 695502" (2 trials). Other intervention names were less common.

The vast majority of trials in "National Institute of Cancer" are 23 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "National Institute of Cancer". undefined are not yet recruiting, 7 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 11 completed trials in National Institute of Cancer, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in National Institute of Cancer, 1 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 17 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".